The Implied Analyst 12-Month Target For IYY
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 16 2025
0mins
Source: NASDAQ.COM
ETF Analyst Target Prices: The iShares Dow Jones U.S. ETF (IYY) has an implied analyst target price of $162.16, indicating an 11.45% upside from its current trading price of $145.50, with notable upside potential in underlying holdings like BILL Holdings Inc, Liberty Global Ltd, and Penumbra Inc.
Investor Considerations: Analysts' target prices may reflect optimism or could be outdated, prompting the need for further research by investors to assess the validity of these targets in light of recent company and industry developments.
Analyst Views on PEN
Wall Street analysts forecast PEN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PEN is 344.64 USD with a low forecast of 266.00 USD and a high forecast of 388.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
14 Buy
1 Hold
0 Sell
Strong Buy
Current: 358.530
Low
266.00
Averages
344.64
High
388.00
Current: 358.530
Low
266.00
Averages
344.64
High
388.00
About PEN
Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
